Publications
2023
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies
Knorr D., Leidner R., Jensen S., Meng R., Jones A., Ballesteros-Merino C., Bell R. B., Baez M., Sprott D., Bifulco C., Piening B., Dahan R., Fox B. A. & Ravetch J. (2023) bioRxiv : the preprint server for biology.
Abstract

Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban N., Yalin A., Landsberger T., Salomon R., Alva A., Feferman T., Amit I. & Dahan R. (2023) Science immunology.
Abstract
2022

Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting
Salomon R., Rotem H., Katzenelenbogen Y., Weiner A., Cohen Saban N., Feferman T., Amit I. & Dahan R. (2022) Nature Cancer.
Abstract

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Salomon R. & Dahan R. (2022) Frontiers in Immunology.
Abstract

Artificial Antigen Presenting Cells for Detection and Desensitization of Autoreactive T cells Associated with Type 1 Diabetes
Artzy-Schnirman A., Abu-Shah E., Chandrawati R., Altman E., Yusuf N., Wang S., Ramos J., Hansel C. S., Haus-Cohen M., Dahan R., Arif S., Dustin M. L., Peakman M., Reiter Y. & Stevens M. M. (2022) Nano Letters.
Abstract

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
He C., Maniyar R. R., Avraham Y., Zappasodi R., Rusinova R., Newman W., Heath H., Wolchok J. D., Dahan R., Merghoub T. & Meyerson J. (2022) Science advances.
Abstract
2021
Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis
Watson A., Li H., Ma B., Weiss R., Bendayan D., Abramovitz L., Ben-Shalom N., Mor M., Pinko E., Bar Oz M., Wang Z., Du F., Lu Y., Rybniker J., Dahan R., Huang H., Barkan D., Xiang Y., Javid B. & Freund N. T. (2021) Nature Communications.
Abstract

Anti-SARS-CoV-2 antibodies elicited by COVID-19mRNA vaccine exhibit a unique glycosylation pattern
Farkash I., Feferman T., Cohen-Saban N., Avraham Y., Morgenstern D., Mayuni G., Barth N., Lustig Y., Miller L., Shouval D. S., Biber A., Kirgner I., Levin Y. & Dahan R. (2021) Cell reports (Cambridge).
Abstract
Unified platform for genetic and serological detection of COVID-19 with single-molecule technology
Furth N., Shilo S., Cohen N., Erez N., Fedyuk V., Schrager A. M., Weinberger A., Dror A. A., Zigron A., Shehadeh M., Sela E., Srouji S., Amit S., Levy I., Segal E., Dahan R., Jones D., Douek D. C. & Shema E. (2021) PLoS ONE.
Abstract
2020
Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis
Indenbaum V., Koren R., Katz-Likvornik S., Yitzchaki M., Halpern O., Regev-Yochay G., Cohen C., Biber A., Feferman T., Saban N. C., Dahan R., Levin T., Gozlan Y., Weil M., Mor O., Mandelboim M., Sofer D., Mendelson E. & Lustig Y. (2020) PLoS ONE.
Abstract

Single-cell genomic approaches for developing the next generation of immunotherapies
Yofe I., Dahan R. & Amit I. (2020) Nature Medicine.
Abstract
2019
BCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer's patches
Biram A., Stromberg A., Winter E., Stoler-Barak L., Salomon R., Addadi Y., Dahan R., Yaari G., Bemark M. & Shulman Z. (2019) Nature Immunology.
Abstract
2018

Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
Knorr D. A., Dahan R. & Ravetch J. (2018) Proceedings Of The National Academy Of Sciences Of The United States Of America-Physical Sciences.
Abstract
2017

Signaling by Antibodies: Recent Progress
Bournazos S., Wang T. T., Dahan R., Maamary J. & Ravetch J. V. (2017) ANNUAL REVIEW OF IMMUNOLOGY.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Vargas F. A., Furness A. J. S., Solomon I., Joshi K., Mekkaoui L., Lesko M. H., Rota E. M., Dahan R., Georgiou A., Sledzinska A., Ben Aissa A. A., Franz D., Sunderland M. W., Wong Y. N. S., Henry J. Y., O'Brien T., Nicol D., Challacombe B., Beers S. A., Turajlic S., Gore M., Larkin J., Swanton C., Chester K. A., Pule M., Ravetch J. V., Marafioti T., Peggs K. S. & Quezada S. A. (2017) Immunity.
2016
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement
Dahan R. & Ravetch J. V. (2016) Cancer Cell.
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Georgoudaki A., Prokopec K. E., Boura V. F., Hellqvist E., Sohn S., Ostling J., Dahan R., Harris R. A., Rantalainen M., Klevebring D., Sund M., Brage S. E., Fuxe J., Rolny C., Li F., Ravetch J. V. & Karlsson M. C. I. (2016) Cell Reports.

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc gamma R Engagement
Dahan R., Barnhart B. C., Li F., Yamniuk A. P., Korman A. J. & Ravetch J. V. (2016) Cancer Cell.
2015

Fc gamma Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan R., Sega E., Engelhardt J., Selby M., Korman A. J. & Ravetch J. V. (2015) Cancer Cell.
2014
HLA-DR alpha 1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis
Meza-Romero R., Benedek G., Yu X., Mooney J. L., Dahan R., Duvshani N., Bucala R., Offner H., Reiter Y., Burrows G. G. & Vandenbark A. A. (2014) Journal of Immunology.
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic A., Bournazos S., DiLillo D. J., Maamary J., Wang T. T., Dahan R., Fiebiger B. & Ravetch J. V. (2014) Nature Immunology.
2013
A novel regulatory pathway for autoimmune disease: Binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance
Vandenbark A. A., Meza-Romero R., Benedek G., Andrew S., Huan J., Chou Y. K., Buenafe A. C., Dahan R., Reiter Y., Mooney J. L., Offner H. & Burrows G. G. (2013) Journal of Autoimmunity.
Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope
Dahan R., Gebe J. A., Preisinger A., James E. A., Tendler M., Nepom G. T. & Reiter Y. (2013) Journal of Autoimmunity.
2012
T-cell-receptor-like antibodies - generation, function and applications
Dahan R. & Reiter Y. (2012) Expert Reviews in Molecular Medicine.
2011
TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexes
Dahan R., Tabul M., Chou Y. K., Meza-Romero R., Andrew S., Ferro A. J., Burrows G. G., Offner H., Vandenbark A. A. & Reiter Y. (2011) European Journal of Immunology.
2008
Analysis of strand transfer and template switching mechanisms of DNA gap repair by homologous recombination in Escherichia coli: Predominance of strand transfer
Izhar L., Goldsmith M., Dahan R., Geacintov N., Lloyd R. G. & Livneh Z. (2008) Journal of Molecular Biology.
Abstract
2007
A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS
Sinha S., Subramanian S., Proctor T. M., Kaler L. J., Grafe M., Dahan R., Huan J., Vandenbark A. A., Burrows G. G. & Offner H. (2007) Journal of Neuroscience.
2004
HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes
Finn T., Jones R., Rich C., Dahan R., Link J., David C., Chou Y., Offner H. & Vandenbark A. (2004) Journal of Neuroscience Research.